{"Clinical Trial ID": "NCT00110084", "Intervention": ["INTERVENTION 1:", "Nab-paclitaxel/Gemcitabine", "Nab (nenoparticle albumin-bound)-Paclitaxel (125mg/m^2)(IV over 30 min) (days 1 and 8) on the 21-day cycle and gemcitabine (1000 mg/m^2)(IV over 30 min) (days 1 and 8) on the 21-day cycle"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Invasive breast cancer confirmed histologically or cytologically", "- Clinical evidence of metastatic disease", "+ No bone metastases or other non-measurable diseases as evidence of metastasis", "A measurable disease, defined as at least 1 measurable injury", "- The following diseases are considered not to be measurable:", "Small lesions (< 2 cm)", "Bone injury", "Nervous system disorders", "Ascites", "Pleural or pericardial discharges", "Inflammatory breast disorders", "- Lymphangitis cutis or pulmonis", "\u2022 Abdominal masses that are not confirmed and followed by imaging techniques", "Cystic lesions", "HER2(human epidermal growth factor receptor 2)-allowed positive disease provided the patient has received prior treatment with trastuzumab", "No signs of active brain metastases, including leptomenal involvement", "- Hormonal receptor status:", "Unspecified", "CHARACTERISTICS OF PATIENTS:", "Age", "- 18 years and over Sex", "Women's Menopausal Status", "\u2022 Unspecified implementation status", "ECOG 0-1 Life expectancy", "At least 12 weeks of haematopoiesis", "Absolute number of neutrophils 1,500/mm3", "Number of platelets 100 000/mm^3", "Hemoglobin 9 g/dL Hepatic", "ASAT and ALT 2.5 times the upper limit of normal (ULN)", "Bilirubine 1.5 times ULN Renal", "Creatinine 1.5 mg/dL Other", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception during and for 30 days after completion of study therapy.", "No pre-existing peripheral neuropathy > grade 1", "No other clinically significant disease or major medical condition that would prevent participation in the study", "No allergy or hypersensitivity to paclitaxel protein-related particles in suspension for injection, paclitaxel, gemcitabine, albumin, excipients of pharmaceutical products or agents that are chemically similar to the drugs under study", "No serious medical risk factor involving any of the major organ systems precludes participation in the study.", "No non-mammary invasive malignancy of stage III or IV active in the last five years", "THERAPE PRIOR CONCURENT:", "Biological therapy", "See Characteristics of the disease Chemotherapy", "Not more than one previous adjuvant chemotherapy", "No previous chemotherapy for metastatic disease", "At least 6 months from previous adjuvant or neoadjuvant taxan", "More than 2 weeks since prior cytotoxic chemotherapy", "Previous authorised neoadjuvant chemotherapy", "No other concomitant chemotherapy Endocrine treatment", "\u2022 Prior hormonal treatment in the form of adjuvant treatment or for a authorised metastatic disease Radiotherapy", "\u2022 Prior radiation therapy to target the lesion is permitted provided there is evidence of disease progression after completion of treatment.", "More than 2 weeks since previous radiation therapy, except for radiation therapy with a non-target lesion only or with a single dose of palliative radiation therapy", "No simultaneous radiation therapy Surgery", "Not specified Other", "More than 2 weeks since previous experimental drugs", "No competing participation in another clinical trial that studies research procedures or therapies", "Concomitant bisphosphonates (e.g., pamidronate or zoledronate) resulted in palliation of pain or lytic lesions due to breast cancer"], "Results": ["Performance measures:", "Proportion of patients with confirmed responses", "The confirmed tumour response (complete and partial) measured by the RECIST criteria(Response Evaluation Criteria In Solid Tumors) on 2 consecutive evaluations of at least 6 weeks interval.", "The confirmed tumour response is at least a 30% decrease in the sum of the longest diameter of the target lesions and no new lesions.", "Timeline: Two consecutive evaluations at least 6 weeks apart", "Results 1:", "Title of arm/group: Nab-paclitaxel/Gemcitabine", "Description of the arm/group: Neb (nenoparticle albumin-bound)-Paclitaxel (125mg/m^2)(IV over 30 min) (days 1 and 8) on the 21-day cycle and gemcitabine (1000 mg/m^2)(IV over 30 min) (days 1 and 8) on the 21-day cycle", "Total number of participants analysed: 50", "Type of measurement: Number", "Unit of measure: Participants Confirmed response: 25", "- Appreciate: 50"], "Adverse Events": ["Undesirable Events 1:", "Total: 11/50 (22.0%)", "Anemia 3/50 (6.0%)", "Febrile neutropenia 1/50 (2.0%)", "Arrhythmia 1/50 (2.0%)", "Ileus 1/50 (2.0%)", "Nausea 1/50 (2.0%)", "Abdominal pain 1/50 (2.0%)", "Vomiting 1/50 (2.0%)", "\u2022 bronchial infection 1/50 (2.0%)", "\u2022 Sepsis 1/50 (2.0%)", "Neutropenia 2/50 (4.0%)", "Decrease in platelet count 1/50 (2.0%)", "Dehydration 1/50 (2.0%)", "- Arthralgia 1/50 (2.0%)"]}